Single spinal fluid injection for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a single injection given into the spinal fluid (intrathecal) to see if it is safe and might slow down ALS. It uses a specially engineered virus (AAV9) to deliver a treatment directly to the nervous system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with ALS (amyotrophic lateral sclerosis) and your symptoms started within the last 3 years
- Your breathing is fairly strong (a breathing test shows at least 70% of the expected value)
- Your ALS rating score is at least 26, and you have good function in the breathing-related items
- You are not currently on certain medications (like riluzole or edaravone) unless you have been on a stable dose for at least 4 weeks
- You have not had gene therapy, stem cell transplants, or organ transplants before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This study tests a new gene therapy called SNUG01 for people with ALS (a disease that weakens muscles). The goal is to see if it's safe and might slow down the disease, especially for those diagnosed within the last 2 years.
This study tests an experimental gene therapy called XT-150, which is given as an injection into the fluid around the spinal cord. The goal is to see if it is safe and to gather information that could help treat ALS muscle weakness.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.